Takeda Pharmaceutical Company Limited (TAK)
Chart Events
Performance Outlook
| Previous Close | 16.43 |
| Open | 16.22 |
| Bid | 16.26 x 3100 |
| Ask | 16.27 x 3000 |
| Day's Range | 16.18 - 16.30 |
| 52 Week Range | 12.28 - 16.58 |
| Volume | |
| Avg. Volume | 2,738,589 |
| Market Cap | 50.811B |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | 24.30 |
| EPS (TTM) | 0.67 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.66 (4.03%) |
| Ex-Dividend Date | Sep 29, 2022 |
| 1y Target Est | 22.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TAK
Related Research
- Takeda Pharmaceutical Company LAnalyst Report: Roche Holding AGRoche Holding AG operates through two segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment focuses on oncology, immunology, ophthalmology, infectious diseases and neuroscience, and the Diagnostics segment specializes in invitro diagnostics. Headquartered in Basel, Switzerland, the company was founded by Fritz Hoffmann-La Roche in 1896. The company has approximately 103,600 employees.RatingFair ValueEconomic Moat2 days agoArgus Research
- American City Business Journals
The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership
Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.
- Benzinga
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced results from a Phase 2b clinical trial of TAK-279 (NDI-034858) in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90, and 100 in the 5mg, 15mg, and 30mg dosing arms compared to placebo at 12 weeks. A significantly greater proportion of TAK-279 patients achieved PASI 7
- Business Wire
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
OSAKA, Japan & CAMBRIDGE, Mass., March 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90 and 100 in the 5mg, 15mg and
